companydata.dkcompanydata.dk

Blue Cell Therapeutics ApS: Financial statements 2025

CVR: 39981610

Source: annual report 2025, Danish Business Authority

01/01/2025 – 31/12/2025

Blue Cell Therapeutics ApS (CVR 39981610) has filed annual accounts for 2025. In 2025, the company reported a gross profit of DKK -5,780,568 and a net result of DKK -21,221,120 compared with DKK -15,189,850 the year before. Equity in the 2025 report amounted to DKK -8,126,690. The company had 9 employees in the financial year.

Gross Profit
DKK -5,780,568
Profit/Loss
DKK -21,221,120
Equity
DKK -8,126,690
Total Assets
DKK 4,823,922
Employees
9

Development

YearRevenueGross ProfitProfit/LossEquityEmployees
2025--5.8M-21.2M-8.1M9
2024--3.1M-15.2M13.1M12
2023--742K-15.3M8.4M14
2022-852K-12.6M9.9M12
2021--844K-14.2M12.5M7

Official annual report

View the official annual report directly on the page with a Pro subscription.

How creditworthy is Blue Cell Therapeutics ApS?

See the CDS score and get a full credit report with recommended credit limit and payment terms.

Read about the CDS score

Events in 2025

Ole Vahlgren joins the board of Blue Cell Therapeutics ApSAug 8, 2025

As of August 8, 2025, Ole Vahlgren has joined the board of directors of Blue Cell Therapeutics ApS.

Olav Hellebø joins the board of Blue Cell Therapeutics ApSAug 8, 2025

As of August 8, 2025, Olav Hellebø has joined the board of directors of Blue Cell Therapeutics ApS.

Anders Vadsholt leaves the board of Blue Cell Therapeutics ApSAug 8, 2025

As of August 8, 2025, Anders Vadsholt has left the board of directors of Blue Cell Therapeutics ApS.

Ole Vahlgren leaves the board of Blue Cell Therapeutics ApSAug 7, 2025

As of August 7, 2025, Ole Vahlgren has left the board of directors of Blue Cell Therapeutics ApS.

Blue Cell Therapeutics ApS: The 2024 annual report is outJun 27, 2025

Blue Cell Therapeutics ApS has published its annual report for 2024. Gross profit came to DKK -3,052,648, and the net result was DKK -15,189,850.

About Blue Cell Therapeutics ApS

Blue Cell Therapeutics ApS is a Danish company of the type Anpartsselskab based in København N, founded in 2018. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The company was previously named Regenerative Therapeutics IVS. The management consists of Søren Paludan Sheikh. The board consists of Olav Hellebø (chair), Anella Rogaczewski, Michael Ulveman and Ole Vahlgren. The company is owned by ANDRÉ ROGACZEWSKI HOLDING II ApS and SPSheikh Holding ApS. The company has 10 employees (2026). In 2025, the company reported a gross profit of DKK -5,780,568 and a net result of DKK -21,221,120 compared with DKK -15,189,850 the year before. Equity in the 2025 report amounted to DKK -8,126,690.

Source: annual report 2025, Danish Business Authority

Other financial years